Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma.
Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, Bleecker E, Busse W, Calhoun WJ, Castro M, Chung KF, Israel E, Jarjour N, Moore W, Peters S, Teague G, Gaston B, Erzurum SC; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Dweik RA, et al. Among authors: israel e. Am J Respir Crit Care Med. 2010 May 15;181(10):1033-41. doi: 10.1164/rccm.200905-0695OC. Epub 2010 Feb 4. Am J Respir Crit Care Med. 2010. PMID: 20133930 Free PMC article.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Among authors: israel e. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study.
Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S. Brightling CE, et al. Among authors: israel e. Ann Allergy Asthma Immunol. 2024 Apr 30:S1081-1206(24)00280-1. doi: 10.1016/j.anai.2024.04.031. Online ahead of print. Ann Allergy Asthma Immunol. 2024. PMID: 38697286
Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma.
Tang M, Charbit AR, Johansson MW, Jarjour NN, Denlinger LC, Raymond WW, Peters MC, Dunican EM, Castro M, Sumino K, Erzurum SC, Comhair SA, Moore WC, Levy BD, Israel E, Phipatanakul W, Phillips BR, Mauger DT, Bleecker ER, Wenzel SE, Fajt ML, Woodruff PG, Hastie AT, Fahy JV; National Heart Lung and Blood Institute Severe Asthma Research Program. Tang M, et al. Among authors: israel e. J Allergy Clin Immunol. 2024 Apr 23:S0091-6749(24)00365-8. doi: 10.1016/j.jaci.2024.03.023. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 38663815 Free article.
A Novel DNase Assay Reveals Low DNase Activity in Severe Asthma.
Charbit AR, Liegeois MA, Raymond WW, Comhair SAA, Johansson MW, Hastie AT, Bleecker ER, Fajt M, Castro M, Sumino K, Erzurum SC, Israel E, Jarjour NN, Mauger DT, Moore WC, Wenzel SE, Woodruff PG, Levy BD, Tang MC, Fahy JV. Charbit AR, et al. Among authors: israel e. Am J Physiol Lung Cell Mol Physiol. 2024 Apr 23. doi: 10.1152/ajplung.00081.2024. Online ahead of print. Am J Physiol Lung Cell Mol Physiol. 2024. PMID: 38651338
665 results